Back to Browse Journals » International Journal of High Throughput Screening » Volume 2

Drug discovery in Parkinson's disease: update and developments in the use of cellular models

Authors Skibinski G, Finkbeiner S

Published Date June 2011 Volume 2011:2 Pages 15—25

DOI http://dx.doi.org/10.2147/IJHTS.S8681

Published 30 June 2011

Gaia Skibinski, Steven Finkbeiner
Gladstone Institute of Neurological Disease, San Francisco, CA, USA

Abstract: Parkinson's disease is the second most common neurodegenerative disorder and is characterized by the degeneration of dopaminergic neurons within the substantia nigra. Dopamine replacement drugs remain the most effective treatment for Parkinson's disease but only provide temporary symptomatic relief. New therapies are urgently needed, but the search for a disease-modifying treatment and a definitive understanding of the underlying mechanisms of Parkinson's disease has been limited by the lack of physiologically relevant models that recapitulate the disease phenotype. The use of immortalized cell lines as in vitro model systems for drug discovery has met with limited success, because efficacy and safety too often fail to translate successfully in human clinical trials. Drug discoverers are shifting their focus to more physiologically relevant cellular models, including primary neurons and stem cells. The recent discovery of induced pluripotent stem cell technology presents an exciting opportunity to derive human dopaminergic neurons from patients with sporadic and familial forms of Parkinson's disease. We anticipate that these human dopaminergic models will recapitulate key features of the Parkinson's disease phenotype. In parallel, high-content screening platforms, which extract information on multiple cellular features within individual neurons, provide a network-based approach that can resolve temporal and spatial relationships underlying mechanisms of neurodegeneration and drug perturbations. These emerging technologies have the potential to establish highly predictive cellular models that could bring about a desperately needed revolution in Parkinson's disease drug discovery.

Keywords: Parkinson's disease, cellular models, drug delivery
Corrigendum

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Other article by this author:

Corrigendum

Skibinski G, Finkbeiner S

International Journal of High Throughput Screening 2011, 2:27-28

Published Date: 22 September 2011

Readers of this article also read:

Sacral insufficiency fractures: a case of mistaken identity

Baldwin MJ, Tucker LJ

International Medical Case Reports Journal 2014, 7:93-98

Published Date: 30 May 2014

Causal diagrams and the logic of matched case-control studies [Corrigendum]

Shahar E, Shahar DJ

Clinical Epidemiology 2014, 6:59-60

Published Date: 22 January 2014

Effect of 6 months of whole body vibration on lumbar spine bone density in postmenopausal women: a randomized controlled trial

Lai CL, Tseng SY, Chen CN, Liao WC, Wang CH, Lee MC, Hsu PS

Clinical Interventions in Aging 2013, 8:1603-1609

Published Date: 4 December 2013

Prolyl-hydroxylase 3: evolving roles for an ancient signaling protein

Place TL, Domann FE

Hypoxia 2013, 1:13-27

Published Date: 16 October 2013

Boston type I keratoprosthesis-donor cornea interface evaluated by high-definition spectral-domain anterior segment optical coherence tomography

Alzaga Fernandez AG, Radcliffe NM, Sippel KC, Rosenblatt MI, Sood P, Starr CE, Ciralsky JB, D'Amico DJ, Kiss S

Clinical Ophthalmology 2012, 6:1355-1359

Published Date: 27 August 2012

Pulmonary thromboendarterectomy after treatment with treprostenil in a chronic thromboembolic pulmonary hypertension patient: a case report

Porpodis K, Konoglou M, Zarogoulidis P, Kaimakamis E, Kontakiotis T, Papakosta D, Zervas V, Katsikogiannis N, Courcoutsakis N, Mitrakas A, Touzopoulos P, Karanikas M, Zarogoulidis K, Markopoulou A

International Journal of General Medicine 2011, 4:767-772

Published Date: 8 November 2011

Emerging options for the management of age-related macular degeneration with stem cells

Ingrid Mooney, James LaMotte

Stem Cells and Cloning: Advances and Applications 2011, 4:1-10

Published Date: 22 December 2010

Development of a functional HTS assay for the APJ receptor

Angela Giddings, Scott Runyon, James Thomas, et al

International Journal of High Throughput Screening 2010, 1:39-47

Published Date: 19 April 2010

Endotoxin-induced IL-6 promoter activation in skeletal muscle requires an NF-κB site

David Yeagley, Charles H Lang

International Journal of Interferon, Cytokine and Mediator Research 2010, 2:9-21

Published Date: 25 January 2010